| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
(-)-Epigallocatechin Gallate (also known as EGCG; epigallocatechin-3-gallate) is a naturally occurring catechin extractied from green tea, which shows multiple bioactivity. (-)-Epigallocatechin gallate functions as a powerful antioxidant, preventing oxidative damage in healthy cells, but also as an antiangiogenic and antitumor agent and as a modulator of tumor cell response to chemotherapy. (-)-Epigallocatechin gallate shows multiple anticancer effects, such as anti-proliferation, anti-angiogenesis, transformation prevention of various cancer cells, cancer cell cycle arrest and inhibition of tumor metastasis.
| Targets |
EGFR; HER2; HER3
|
|---|---|
| ln Vitro |
In a dose-dependent manner, (-)-Epigallocatechin Gallate (EGCG, 10-60 μM) suppresses the development of WRO and FB-2 cells [1]. (-)-Epigallocatechin Gallate (10–60 μM, 0–24 h) raises the expression of p21 and p53 and decreases the phosphorylation of cyclin D1, AKT, and ERK1/2 [1]. The effects of (10–60 μM, 12 hours)-Epigallocatechin Gallate on cell motility and migration are reported [1]. According to a biochemical experiment, (-)-Epigallocatechin Gallate (0 – 20 μM, or roughly 0 – 20 minutes) suppresses GLUD1/2 and IDH1 activities in a concentration- and time-dependent manner [2]. (-)- Epigallocatechin Gallate (0-35 μg/mL, 24-72 hours) promotes cell apoptosis, reduces G0/G1 phase cell proliferation, and suppresses the proliferation of colorectal cancer cells (LoVo, SW480, HT-29, and HCT-8 cells)[3]. In osteoblasts, LPS-induced COX-2 and mPGES-1 mRNA expression as well as prostaglandin E2 synthesis are inhibited by (-)-Epigallocatechin Gallate (30 μM, 3–24 h) [4].
|
| ln Vivo |
(-)- Epigallocatechin Gallate inhibits the growth of tumors when given intraperitoneally (5–20 mg/kg) once day for 14 days in an orthotopic transplantation paradigm [3]. (-)- The LPS-induced loss of bone mineral density (BMD) is inhibited and reduced when epigallocatechin gallate is injected into the lower gums of mice in an experimental periodontitis model at a single dose of 0.5 mg/mouse [3].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: FB-2 and WRO cells (serum-starved for 48h) Tested Concentrations: 10, 40, 60 μM. Incubation Duration: 4 days Experimental Results: Inhibited basal cell proliferation (40% in FB-2 and 35% in WRO) at 10 μM, inhibited cell number (by 68% to 73%) at 40 and 60 μM). Western Blot Analysis[1] Cell Types: FB-2 cells Tested Concentrations: 10, 40, 60 μM. Incubation Duration: 24 h Experimental Results: decreased cyclin D1 level, phosphorylation of AKT and ERK1/2. Induced the expression of p21 and p53, and E-cadherin, N-cadherin, Vimentin and α5-integrin. Cell Migration Assay [1] Cell Types: FB-2 and WRO cells (serum-starved for 48h) Tested Concentrations: 10, 40, 60 μM. Incubation Duration: 12 h Experimental Results: decreased migration activity in FB-2 and WRO cells. RT-PCR[4] Cell Types: Mouse primary osteoblasts (1 ng/ml LPS-treated) Tested Concentrations: 30 μM Incubation Duration: 3, 6, 12, 24 h Experimental Results: Suppressed the LPS-induced expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production. |
| Animal Protocol |
Animal/Disease Models: Orthotopic transplant BALB/c nude mice model[3]
Doses: 5, 10, and 20 mg/kg, one time/day for 14 days. Route of Administration: Intragastrical administration. Experimental Results: Inhibited tumors growth with no liver or lung metastases. Animal/Disease Models: Model of experimental periodontitis, LPS (25 μg/mouse)[4] Doses: 0.5 mg/mouse, a single dose. Route of Administration: Injected into the mouse lower gingiva Experimental Results: Inhibited the LPS-induced loss of bone mineral density (BMD ) in mice. |
| References |
[1]. De Amicis F, et al. Epigallocatechin gallate inhibits growth and Epithelial-to-Mesenchymal Transition in human thyroid carcinoma cell lines. J Cell Physiol. 2013 Apr 1.
[2]. Peeters TH, et al. Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. Cancer Metab. 2019 May 20;7:4. [3]. Jin H, et al. Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling. Onco Targets Ther. 2013;6:145-53. [4]. Tsukasa Tominari; Epigallocatechin gallate (EGCG) suppresses lipopolysaccharide-induced inflammatory bone resorption, and protects against alveolar bone loss in mice. FEBS Open Bio. 2015 Jun 12;5:522-7. |
| Molecular Formula |
C22H18O11
|
|
|---|---|---|
| Molecular Weight |
458.37
|
|
| Exact Mass |
458.084911
|
|
| Elemental Analysis |
C, 57.65; H, 3.96; O, 38.40
|
|
| CAS # |
989-51-5
|
|
| Related CAS # |
(-)-Epigallocatechin;970-74-1;(-)-Gallocatechin gallate;4233-96-9;(-)-Epigallocatechin Gallate (Standard);989-51-5;(+/-)-Epigallocatechin Gallate-13C3
|
|
| Appearance |
Off-white to pink solid powder
|
|
| Source |
polyphenol in green tea
|
|
| LogP |
1.2
|
|
| tPSA |
197A^2
|
|
| SMILES |
O1C2=C([H])C(=C([H])C(=C2C([H])([H])[C@]([H])([C@@]1([H])C1C([H])=C(C(=C(C=1[H])O[H])O[H])O[H])OC(C1C([H])=C(C(=C(C=1[H])O[H])O[H])O[H])=O)O[H])O[H]
|
|
| InChi Key |
WMBWREPUVVBILR-WIYYLYMNSA-N
|
|
| InChi Code |
InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1
|
|
| Chemical Name |
[(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.54 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.54 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.54 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 9.09 mg/mL (19.83 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1816 mL | 10.9082 mL | 21.8164 mL | |
| 5 mM | 0.4363 mL | 2.1816 mL | 4.3633 mL | |
| 10 mM | 0.2182 mL | 1.0908 mL | 2.1816 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA